Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports

Immune checkpoint inhibitor-induced colitis: A comprehensive review

(2019) Aniruddh Som et al.   World Journal of Clinical Cases

The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review

(2018) Ryosuke Yamauchi et al.   BMC GASTROENTEROLOGY

Immune Checkpoint Inhibitor-Associated Colits and Hepatitis

(2018) Haritha G. Reddy et al.   Clinical and Translational Gastroenterology

Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases

(2017) Julian Panes et al.   GASTROENTEROLOGY

Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma

(2017) Fumie Igari et al.   HUMAN PATHOLOGY

Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities

(2017) Clélia Coutzac et al.   Journal of Crohns & Colitis

Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases

(2016) Mei Lan Chen et al.   INFLAMMATORY BOWEL DISEASES

C-Reactive Protein As a Marker of Melanoma Progression

(2015) Shenying Fang et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2015) Scott N. Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

(2015) Ahmad A. Tarhini et al.   Journal for ImmunoTherapy of Cancer

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

(2014) Ester Simeone et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab

(2013) Jeffrey S. Weber et al.   CANCER

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

α-CTLA-4 mAb-associated Panenteritis

(2009) Darryl A. Oble et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells

(2009) James D. Lord et al.   DIGESTIVE DISEASES AND SCIENCES

Interleukin-23/Th17 pathways and inflammatory bowel disease

(2009) Clara Abraham et al.   INFLAMMATORY BOWEL DISEASES